Navigation Links
EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting

Antiproliferative and Antiangiogenic Activity Demonstrated in Preclinical Leukemia and Breast Cancer Models

ROCKVILLE, Md., April 17, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical data for its clinical-stage product candidate, ENMD-1198. The data were presented by EntreMed scientists and collaborators during two separate sessions at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California.

ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2-methoxyestradiol (2ME2), is designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1 alpha. In preclinical studies, ENMD-1198 has been shown to be an orally active, antimitotic agent that leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.

Results demonstrate that oral administration of ENMD-1198 was well tolerated and produced significant dose-dependent antitumor activity in a preclinical breast tumor model. Histologic staining and evaluation of tumor sections from the breast cancer model demonstrated a decrease in HIF-1 alpha, tumor cell growth (PCNA), and angiogenesis (CD31). HIF-1 alpha is a protein that is upregulated in many human tumors and has been shown to promote tumorigenesis and decrease tumor cell sensitivity to anticancer agents.

In a separate preclinical study, conducted by EntreMed collaborators at the Children's Cancer Institute Australia for Medical Research and the University of New South Wales, ENMD-1198 demonstrated antitumor activity against vinca alkaloid (micro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... PARK, N.J. , Aug. 3, 2015 ... and secondary endpoints in a phase III study (COMPOSE ... adult patients with chronic non-cancer pain. Naldemedine is an ... is the third Phase III trial in which naldemedine ... Study results showed that a 0.2 mg tablet of ...
(Date:8/3/2015)... Aug. 3, 2015  Encision Inc. (PK:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... ended June 30, 2015. The Company posted ... net loss of $213 thousand, or $(0.02) per share. ... for a net loss of $202 thousand, or $(0.02) ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® ... collaborators at the 14th Annual Meeting of the American Society ... in Seattle from May 18-21, 2011. "Sangamo,s ...
... Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), ... clinical data highlighting the safety profile of EXPAREL™ ... the 2011 International Anesthesia Research Society (IARS) Annual ... Comprehensive, program-wide safety data for EXPAREL will be ...
Cached Medicine Technology:Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 2Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 3Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 5
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July ... diet leads to one pound of weight loss may not be accurate. While this system ... to one pound of fat varies – based both on the individual and at what ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... ... the highest honors in the industry. , ... (PRWEB) March 8, 2010 -- The Sturge-Weber Foundation honored renowned dermatologist Dr. David J. Goldberg with ... 2010. Dr. Goldberg is a pioneer in the field of dermatology and director ...
... ... ... ... ...
... developed a new mathematical approach to analyze molecular data ... when combined with well-established techniques, readily identifies changes in ... potential to distinguish between health and disease states. ... Ph.D., of Stanford University, Calif., the team of investigators ...
... Doctors should do more to explain test results, researchers find ... do a better job of explaining genomic test results to ... which analyzes 21 genes in breast tumors removed during surgery ... can help guide decisions about the use of chemotherapy in ...
... , ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 2Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 2Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 4Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 5Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 6Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 2Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 3Health News:Breast Cancer Patients Often Confused by Genomic Testing 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 4Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 5Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 2Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 3Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 4Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: